CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 187 enrolled
Drug / intervention
Nicotine lower dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01466361
NCT01466361Phase 2Completed
CompareCT.gov

Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving

GlaxoSmithKline·interventional·Posted Nov 7, 2011·Updated Aug 28, 2019

In Brief

A Phase 2 clinical trial evaluating Nicotine lower dose, Nicotine higher dose, and 1 other intervention for Smoking and Smoking Cessation. Completed, enrolled 187 participants across 1 site.

Detailed Summary

This study is designed to evaluate the ability of a nicotine lozenge to relieve craving for a cigarette compared to a matched placebo (a placebo is like sugar pill and contains no active).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking, Smoking Cessation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 7, 2011
Enrollment StartSep 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.7 years ago

Interventions

Nicotine lower dosedrug

lower dose nicotine lozenge

Nicotine higher dosedrug

higher dose nicotine lozenge

Placebodrug

placebo